Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seunguk Oh

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Journal of Neuro-Oncology|December 18, 2007
Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft modelBrad J Stish, Seunguk Oh, Daniel A Vallera
Oral Oncology|July 24, 2012
Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinomaNate N Waldron, Seunguk Oh, Daniel A Vallera
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|August 23, 2011
Morphine induces splenocyte trafficking into the CNSMichael Olin, Seunguk Oh, Sabita Roy, et al.
Molecular Cancer Therapeutics|June 10, 2010
Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastasesDaniel A Vallera, Seunguk Oh, Hua Chen, et al.
Journal of Neurosurgery|February 8, 2011
Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brainSeunguk Oh, Alexander K Tsai, John R Ohlfest, et al.
Journal of Neuro-Oncology|September 11, 2010
A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculatureAlexander K Tsai, Seunguk Oh, Hua Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinomaSeunguk Oh, Brad J Stish, Deepali Sachdev, et al.
Pancreas|January 20, 2012
A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic modelSeunguk Oh, Deborah A Todhunter, Angela Panoskaltsis-Mortari, et al.
Pancreas|February 26, 2010
A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancerSeunguk Oh, Brad J Stish, Selwyn M Vickers, et al.
Molecular Cancer Therapeutics|August 25, 2011
Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancerNate N Waldron, Dan S Kaufman, Seunguk Oh, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of Neuro-Oncology|December 18, 2007
Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft modelBrad J Stish, Seunguk Oh, Daniel A Vallera
Oral Oncology|July 24, 2012
Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinomaNate N Waldron, Seunguk Oh, Daniel A Vallera
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|August 23, 2011
Morphine induces splenocyte trafficking into the CNSMichael Olin, Seunguk Oh, Sabita Roy, et al.
Molecular Cancer Therapeutics|June 10, 2010
Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastasesDaniel A Vallera, Seunguk Oh, Hua Chen, et al.
Journal of Neurosurgery|February 8, 2011
Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brainSeunguk Oh, Alexander K Tsai, John R Ohlfest, et al.
Journal of Neuro-Oncology|September 11, 2010
A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculatureAlexander K Tsai, Seunguk Oh, Hua Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinomaSeunguk Oh, Brad J Stish, Deepali Sachdev, et al.
Pancreas|January 20, 2012
A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic modelSeunguk Oh, Deborah A Todhunter, Angela Panoskaltsis-Mortari, et al.
Pancreas|February 26, 2010
A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancerSeunguk Oh, Brad J Stish, Selwyn M Vickers, et al.
Molecular Cancer Therapeutics|August 25, 2011
Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancerNate N Waldron, Dan S Kaufman, Seunguk Oh, et al.
Pageof 2